pmc-enju-pas Home  

PMC:1064895 / 16120-16968 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T11795 0-9 VB denotes Increased
T11796 10-15 NN denotes IL-17
T11797 16-26 NN denotes production
T11798 27-29 IN denotes in
T11799 30-34 NN denotes PBMC
T11800 35-37 IN denotes of
T11801 38-46 NN denotes patients
T11802 47-51 IN denotes with
T11803 52-54 NN denotes RA
T11804 55-57 IN denotes by
T11805 58-66 JJ denotes anti-CD3
T11806 67-73 CC denotes and/or
T11807 74-83 NN denotes anti-CD28
T11808 83-84 -COMMA- denotes ,
T11809 85-88 CC denotes and
T11810 89-92 NN denotes PHA
T11811 93-100 IN denotes Because
T11812 101-106 NN denotes IL-17
T11813 107-110 VB denotes was
T11814 111-118 RB denotes already
T11815 119-124 VB denotes known
T11816 125-129 IN denotes from
T11817 130-137 JJ denotes earlier
T11818 138-145 NN denotes reports
T11819 146-148 TO denotes to
T11820 149-151 VB denotes be
T11821 152-160 VB denotes produced
T11822 161-167 RB denotes mainly
T11823 168-170 IN denotes by
T11824 171-180 VB denotes activated
T11825 181-182 NN denotes T
T11826 183-188 NN denotes cells
T11827 188-189 -COMMA- denotes ,
T11828 190-192 PRP denotes we
T11829 193-205 VB denotes investigated
T11830 206-209 DT denotes the
T11831 210-216 NN denotes effect
T11832 217-219 IN denotes of
T11833 220-229 JJ denotes different
T11834 230-244 NN denotes concentrations
T11835 245-247 IN denotes of
T11836 248-256 NN denotes anti-CD3
T11837 257-258 -LRB- denotes (
T11838 258-259 CD denotes 1
T11839 259-260 -COMMA- denotes ,
T11840 261-262 CD denotes 5
T11841 263-266 CC denotes and
T11842 267-269 CD denotes 10
T11843 270-275 NN denotes μg/ml
T11844 275-276 -RRB- denotes )
T11845 277-279 IN denotes as
T11846 280-281 DT denotes a
T11847 282-283 NN denotes T
T11848 284-288 NN denotes cell
T11849 289-299 NN denotes activation
T11850 299-300 -COMMA- denotes ,
T11851 301-306 WDT denotes which
T11852 307-313 VB denotes showed
T11853 314-315 DT denotes a
T11854 316-330 JJ denotes dose-dependent
T11855 331-339 NN denotes increase
T11856 340-342 IN denotes in
T11857 343-348 NN denotes IL-17
T11858 349-355 NN denotes levels
T11859 356-357 -LRB- denotes (
T11860 357-361 NN denotes data
T11861 362-365 RB denotes not
T11862 366-371 VB denotes shown
T11863 371-372 -RRB- denotes )
T11864 374-376 IN denotes On
T11865 377-380 DT denotes the
T11866 381-386 NN denotes basis
T11867 387-389 IN denotes of
T11868 390-394 DT denotes this
T11869 394-395 -COMMA- denotes ,
T11870 396-398 PRP denotes we
T11871 399-404 VB denotes chose
T11872 405-407 CD denotes 10
T11873 408-413 NN denotes μg/ml
T11874 414-416 IN denotes as
T11875 417-418 DT denotes a
T11876 419-430 NN denotes stimulation
T11877 431-444 NN denotes concentration
T11878 445-448 IN denotes for
T11879 449-457 NN denotes anti-CD3
T11880 459-461 IN denotes As
T11881 462-467 VB denotes shown
T11882 468-470 IN denotes in
T11883 471-476 JJ denotes Table
T11884 477-478 CD denotes 1
T11885 478-479 -COMMA- denotes ,
T11886 480-488 JJ denotes anti-CD3
T11887 489-502 RB denotes significantly
T11888 503-514 VB denotes upregulated
T11889 515-520 NN denotes IL-17
T11890 521-531 NN denotes production
T11891 532-534 IN denotes up
T11892 535-537 TO denotes to
T11893 538-546 RB denotes 3.7-fold
T11894 546-547 -COMMA- denotes ,
T11895 548-551 CC denotes and
T11896 552-555 DT denotes the
T11897 556-567 NN denotes combination
T11898 568-570 IN denotes of
T11899 571-580 NN denotes anti-CD28
T11900 581-584 CC denotes and
T11901 585-593 NN denotes anti-CD3
T11902 594-602 VB denotes produced
T11903 603-607 JJ denotes more
T11904 608-613 NN denotes IL-17
T11905 614-615 -LRB- denotes (
T11906 615-628 RB denotes approximately
T11907 629-641 RB denotes 1.3-1.5-fold
T11908 641-642 -RRB- denotes )
T11909 643-647 IN denotes than
T11910 648-656 NN denotes anti-CD3
T11911 657-662 RB denotes alone
T11912 664-675 RB denotes Furthermore
T11913 675-676 -COMMA- denotes ,
T11914 677-681 WRB denotes when
T11915 682-691 VB denotes incubated
T11916 692-696 IN denotes with
T11917 697-698 NN denotes T
T11918 699-703 NN denotes cell
T11919 704-712 NN denotes mitogens
T11920 713-717 JJ denotes such
T11921 718-720 IN denotes as
T11922 721-724 NN denotes PHA
T11923 724-725 -COMMA- denotes ,
T11924 726-735 VB denotes increased
T11925 736-741 NN denotes IL-17
T11926 742-752 NN denotes production
T11927 753-756 VB denotes was
T11928 757-761 RB denotes more
T11929 762-772 JJ denotes pronounced
T11930 773-777 IN denotes than
T11931 778-782 IN denotes with
T11932 783-791 JJ denotes anti-CD3
T11933 792-795 CC denotes and
T11934 796-805 JJ denotes anti-CD28
T11935 806-807 -LRB- denotes (
T11936 807-810 CD denotes 588
T11937 811-812 SYM denotes ±
T11938 813-815 CD denotes 85
T11939 816-822 IN denotes versus
T11940 823-826 CD denotes 211
T11941 827-828 SYM denotes ±
T11942 829-830 CD denotes 1
T11943 831-836 NN denotes pg/ml
T11944 836-837 -COLON- denotes ;
T11945 838-839 NN denotes P
T11946 840-841 SYM denotes <
T11947 842-846 CD denotes 0.05
T11948 846-847 -RRB- denotes )
R6340 T11797 T11795 arg2Of production,Increased
R6341 T11797 T11796 arg1Of production,IL-17
R6342 T11797 T11798 arg1Of production,in
R6343 T11797 T11804 arg1Of production,by
R6344 T11799 T11798 arg2Of PBMC,in
R6345 T11799 T11800 arg1Of PBMC,of
R6346 T11801 T11800 arg2Of patients,of
R6347 T11801 T11802 arg1Of patients,with
R6348 T11803 T11802 arg2Of RA,with
R6349 T11805 T11806 arg1Of anti-CD3,and/or
R6350 T11806 T11809 arg1Of and/or,and
R6351 T11807 T11806 arg2Of anti-CD28,and/or
R6352 T11809 T11804 arg2Of and,by
R6353 T11809 T11808 arg1Of and,","
R6354 T11810 T11809 arg2Of PHA,and
R6355 T11812 T11813 arg1Of IL-17,was
R6356 T11812 T11815 arg2Of IL-17,known
R6357 T11815 T11811 arg2Of known,Because
R6358 T11815 T11813 arg2Of known,was
R6359 T11815 T11814 arg1Of known,already
R6360 T11815 T11816 arg1Of known,from
R6361 T11818 T11816 arg2Of reports,from
R6362 T11818 T11817 arg1Of reports,earlier
R6363 T11818 T11819 modOf reports,to
R6364 T11818 T11820 arg1Of reports,be
R6365 T11818 T11821 arg2Of reports,produced
R6366 T11821 T11819 arg1Of produced,to
R6367 T11821 T11820 arg2Of produced,be
R6368 T11821 T11822 arg1Of produced,mainly
R6369 T11826 T11821 arg1Of cells,produced
R6370 T11826 T11823 arg2Of cells,by
R6371 T11826 T11824 arg2Of cells,activated
R6372 T11826 T11825 arg1Of cells,T
R6373 T11828 T11829 arg1Of we,investigated
R6374 T11829 T11811 arg1Of investigated,Because
R6375 T11829 T11827 arg1Of investigated,","
R6376 T11829 T11845 arg1Of investigated,as
R6377 T11831 T11829 arg2Of effect,investigated
R6378 T11831 T11830 arg1Of effect,the
R6379 T11831 T11832 arg1Of effect,of
R6380 T11834 T11832 arg2Of concentrations,of
R6381 T11834 T11833 arg1Of concentrations,different
R6382 T11834 T11835 arg1Of concentrations,of
R6383 T11834 T11837 arg1Of concentrations,(
R6384 T11836 T11835 arg2Of anti-CD3,of
R6385 T11838 T11839 arg1Of 1,","
R6386 T11839 T11841 arg1Of ",",and
R6387 T11840 T11839 arg2Of 5,","
R6388 T11842 T11841 arg2Of 10,and
R6389 T11843 T11837 arg2Of μg/ml,(
R6390 T11843 T11838 arg1Of μg/ml,1
R6391 T11843 T11840 arg1Of μg/ml,5
R6392 T11843 T11842 arg1Of μg/ml,10
R6393 T11844 T11837 arg3Of ),(
R6394 T11849 T11845 arg2Of activation,as
R6395 T11849 T11846 arg1Of activation,a
R6396 T11849 T11847 arg1Of activation,T
R6397 T11849 T11848 arg1Of activation,cell
R6398 T11849 T11850 arg1Of activation,","
R6399 T11849 T11851 arg1Of activation,which
R6400 T11849 T11852 arg1Of activation,showed
R6401 T11855 T11852 arg2Of increase,showed
R6402 T11855 T11853 arg1Of increase,a
R6403 T11855 T11854 arg1Of increase,dose-dependent
R6404 T11855 T11856 arg1Of increase,in
R6405 T11858 T11856 arg2Of levels,in
R6406 T11858 T11857 arg1Of levels,IL-17
R6407 T11858 T11859 arg1Of levels,(
R6408 T11860 T11859 arg2Of data,(
R6409 T11860 T11862 arg2Of data,shown
R6410 T11862 T11861 arg1Of shown,not
R6411 T11863 T11859 arg3Of ),(
R6412 T11866 T11864 arg2Of basis,On
R6413 T11866 T11865 arg1Of basis,the
R6414 T11866 T11867 arg1Of basis,of
R6415 T11868 T11867 arg2Of this,of
R6416 T11870 T11871 arg1Of we,chose
R6417 T11871 T11864 arg1Of chose,On
R6418 T11871 T11869 arg1Of chose,","
R6419 T11871 T11874 arg1Of chose,as
R6420 T11873 T11871 arg2Of μg/ml,chose
R6421 T11873 T11872 arg1Of μg/ml,10
R6422 T11877 T11874 arg2Of concentration,as
R6423 T11877 T11875 arg1Of concentration,a
R6424 T11877 T11876 arg1Of concentration,stimulation
R6425 T11877 T11878 arg1Of concentration,for
R6426 T11879 T11878 arg2Of anti-CD3,for
R6427 T11881 T11880 arg2Of shown,As
R6428 T11881 T11882 arg1Of shown,in
R6429 T11884 T11882 arg2Of 1,in
R6430 T11884 T11883 arg1Of 1,Table
R6431 T11886 T11888 arg1Of anti-CD3,upregulated
R6432 T11888 T11880 arg1Of upregulated,As
R6433 T11888 T11885 arg1Of upregulated,","
R6434 T11888 T11887 arg1Of upregulated,significantly
R6435 T11888 T11895 arg1Of upregulated,and
R6436 T11890 T11888 arg2Of production,upregulated
R6437 T11890 T11889 arg1Of production,IL-17
R6438 T11890 T11892 arg1Of production,to
R6439 T11892 T11891 arg1Of to,up
R6440 T11893 T11892 arg2Of 3.7-fold,to
R6441 T11895 T11894 arg1Of and,","
R6442 T11897 T11896 arg1Of combination,the
R6443 T11897 T11898 arg1Of combination,of
R6444 T11897 T11902 arg1Of combination,produced
R6445 T11899 T11900 arg1Of anti-CD28,and
R6446 T11900 T11898 arg2Of and,of
R6447 T11901 T11900 arg2Of anti-CD3,and
R6448 T11902 T11895 arg2Of produced,and
R6449 T11902 T11905 arg1Of produced,(
R6450 T11902 T11909 arg1Of produced,than
R6451 T11904 T11902 arg2Of IL-17,produced
R6452 T11904 T11903 arg1Of IL-17,more
R6453 T11907 T11905 arg2Of 1.3-1.5-fold,(
R6454 T11907 T11906 arg1Of 1.3-1.5-fold,approximately
R6455 T11908 T11905 arg3Of ),(
R6456 T11910 T11909 arg2Of anti-CD3,than
R6457 T11910 T11911 arg1Of anti-CD3,alone
R6458 T11915 T11914 arg2Of incubated,when
R6459 T11915 T11916 arg1Of incubated,with
R6460 T11919 T11916 arg2Of mitogens,with
R6461 T11919 T11917 arg1Of mitogens,T
R6462 T11919 T11918 arg1Of mitogens,cell
R6463 T11919 T11921 arg1Of mitogens,as
R6464 T11921 T11920 arg1Of as,such
R6465 T11922 T11921 arg2Of PHA,as
R6466 T11926 T11915 arg1Of production,incubated
R6467 T11926 T11924 arg2Of production,increased
R6468 T11926 T11925 arg1Of production,IL-17
R6469 T11926 T11927 arg1Of production,was
R6470 T11926 T11929 arg1Of production,pronounced
R6471 T11927 T11912 arg1Of was,Furthermore
R6472 T11927 T11913 arg1Of was,","
R6473 T11927 T11914 arg1Of was,when
R6474 T11927 T11923 arg1Of was,","
R6475 T11929 T11927 arg2Of pronounced,was
R6476 T11929 T11928 arg1Of pronounced,more
R6477 T11929 T11930 arg1Of pronounced,than
R6478 T11929 T11935 arg1Of pronounced,(
R6479 T11931 T11930 arg2Of with,than
R6480 T11932 T11933 arg1Of anti-CD3,and
R6481 T11933 T11931 arg2Of and,with
R6482 T11934 T11933 arg2Of anti-CD28,and
R6483 T11942 T11939 arg1Of 1,versus
R6484 T11942 T11940 arg1Of 1,211
R6485 T11942 T11941 arg1Of 1,±
R6486 T11943 T11935 arg2Of pg/ml,(
R6487 T11943 T11936 arg1Of pg/ml,588
R6488 T11943 T11937 arg1Of pg/ml,±
R6489 T11943 T11938 arg1Of pg/ml,85
R6490 T11943 T11942 arg1Of pg/ml,1
R6491 T11943 T11944 arg1Of pg/ml,;
R6492 T11945 T11944 arg2Of P,;
R6493 T11945 T11946 arg1Of P,<
R6494 T11945 T11947 arg1Of P,0.05
R6495 T11948 T11935 arg3Of ),(